Harvard Bioscience Inc expected to post a loss of 1 cent a share - Earnings Preview
Harvard Bioscience Inc
HBIO is expected to show a fall in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025The Holliston Massachusetts-based company is expected to report a 11.7% decrease in revenue to $20.4 million from $23.1 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on May 12 2025, for the period ended June 30, was for revenue between $18.00 million and $20.00 million.
LSEG's mean analyst estimate for Harvard Bioscience Inc is for a loss of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Harvard Bioscience Inc is $3.00, about 85.5% above its last closing price of $0.44
The company's guidance on May 12 2025 for the period ended June 30 was for gross profit margin between USD55% and USD57%.
This summary was machine generated August 4 at 13:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
